One Nucleus and Sanger Institute form partnership
The Wellcome Trust Sanger Institute has become the latest partner to join forces with life science members’ organisation One Nucleus.
The Cambridge alliance includes the Institute being an official supporter for One Nucleus’ annual translational conference ON Helix – being held at the newly refurbished Wellcome Trust Conference Centre on July 14.
Dr Martin Dougherty, COO of Sanger Institute and the Wellcome Genome Campus said: “At the Wellcome Trust Sanger Institute we aim to ensure our world class scientific research is brought to the clinic, and the conversations and interactions that One Nucleus fosters will help us to achieve that.
“These are immensely exciting times for genomics research for the Wellcome Trust Sanger Institute and for the Wellcome Genome Campus but above all, with the support of One Nucleus, for biomedicine in this region.”
The Wellcome Genome Campus is a 125-acre estate south of Cambridge near Hinxton village. It is home to the Wellcome Trust Sanger Institute, the European Molecular Biology Laboratory’s European Bioinformatics Institute, the Centre for Therapeutic Target Validation and a number of spin-off companies.
They will shortly also be joined by Genomics England as it directs the 100,000 Genomes project, with sequencing supplier Illumina housed in a brand new sequencing building on-site.
Spring 2016 will see the opening of the Biodata Innovation Centre, enabling a growing number of commercial sector collaborators to join the campus community, supporting a shared vision of delivering life changing science. ON Helix is a one day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business. The opening keynote address will be delivered by Dr Bahija Jallal, head of MedImmune and vice-president AstraZeneca and other keynote speakers include George Freeman, the UK’s Minister for life sciences.
• PHOTOGRAPH SHOWS: Bahija Jallal, head of MedImmune